Global Respiratory Syncytial Virus Vaccine for the Elderly Market Growth 2026-2032
The global Respiratory Syncytial Virus Vaccine for the Elderly market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
United States market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Respiratory Syncytial Virus Vaccine for the Elderly players cover GSK, Pfizer, Moderna, Daiichi Sankyo, Icosavax, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Respiratory Syncytial Virus Vaccine for the Elderly Industry Forecast” looks at past sales and reviews total world Respiratory Syncytial Virus Vaccine for the Elderly sales in 2025, providing a comprehensive analysis by region and market sector of projected Respiratory Syncytial Virus Vaccine for the Elderly sales for 2026 through 2032. With Respiratory Syncytial Virus Vaccine for the Elderly sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Respiratory Syncytial Virus Vaccine for the Elderly industry.
This Insight Report provides a comprehensive analysis of the global Respiratory Syncytial Virus Vaccine for the Elderly landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Respiratory Syncytial Virus Vaccine for the Elderly portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Respiratory Syncytial Virus Vaccine for the Elderly market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Respiratory Syncytial Virus Vaccine for the Elderly and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Respiratory Syncytial Virus Vaccine for the Elderly.
This report presents a comprehensive overview, market shares, and growth opportunities of Respiratory Syncytial Virus Vaccine for the Elderly market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Respiratory Syncytial Virus Vaccine for the Elderly market?
What factors are driving Respiratory Syncytial Virus Vaccine for the Elderly market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Respiratory Syncytial Virus Vaccine for the Elderly market opportunities vary by end market size?
How does Respiratory Syncytial Virus Vaccine for the Elderly break out by Type, by Application?
United States market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Respiratory Syncytial Virus Vaccine for the Elderly players cover GSK, Pfizer, Moderna, Daiichi Sankyo, Icosavax, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Respiratory Syncytial Virus Vaccine for the Elderly Industry Forecast” looks at past sales and reviews total world Respiratory Syncytial Virus Vaccine for the Elderly sales in 2025, providing a comprehensive analysis by region and market sector of projected Respiratory Syncytial Virus Vaccine for the Elderly sales for 2026 through 2032. With Respiratory Syncytial Virus Vaccine for the Elderly sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Respiratory Syncytial Virus Vaccine for the Elderly industry.
This Insight Report provides a comprehensive analysis of the global Respiratory Syncytial Virus Vaccine for the Elderly landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Respiratory Syncytial Virus Vaccine for the Elderly portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Respiratory Syncytial Virus Vaccine for the Elderly market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Respiratory Syncytial Virus Vaccine for the Elderly and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Respiratory Syncytial Virus Vaccine for the Elderly.
This report presents a comprehensive overview, market shares, and growth opportunities of Respiratory Syncytial Virus Vaccine for the Elderly market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Recombinant Protein Vaccine
- Nucleic Acid Vaccines
- Others
- Hospital
- Centers for Disease Control and Prevention
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- GSK
- Pfizer
- Moderna
- Daiichi Sankyo
- Icosavax
- Sanofi
- Blue Lake Biotechnology
- Advaccine
- Starna Therapeutics
- Immorna
- Clover Biopharma
- Innorna
- RNAimmune
What is the 10-year outlook for the global Respiratory Syncytial Virus Vaccine for the Elderly market?
What factors are driving Respiratory Syncytial Virus Vaccine for the Elderly market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Respiratory Syncytial Virus Vaccine for the Elderly market opportunities vary by end market size?
How does Respiratory Syncytial Virus Vaccine for the Elderly break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Respiratory Syncytial Virus Vaccine for the Elderly by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Respiratory Syncytial Virus Vaccine for the Elderly by Country/Region, 2021, 2025 & 2032
2.2 Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type
2.2.1 Recombinant Protein Vaccine
2.2.2 Nucleic Acid Vaccines
2.2.3 Others
2.2.4 Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type
2.2.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
2.2.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Type (2021-2026)
2.3 Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application
2.3.1 Hospital
2.3.2 Centers for Disease Control and Prevention
2.3.3 Others
2.3.4 Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application
2.3.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Market Share by Application (2021-2026)
2.3.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Breakdown Data by Company
3.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales by Company (2021-2026)
3.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Company (2021-2026)
3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue by Company (2021-2026)
3.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company (2021-2026)
3.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Company (2021-2026)
3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Company
3.4 Key Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Product Location Distribution
3.4.2 Players Respiratory Syncytial Virus Vaccine for the Elderly Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY BY GEOGRAPHIC REGION
4.1 World Historic Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Geographic Region (2021-2026)
4.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country/Region (2021-2026)
4.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales by Country/Region (2021-2026)
4.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue by Country/Region (2021-2026)
4.3 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth
4.4 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth
4.5 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth
4.6 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth
5 AMERICAS
5.1 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country
5.1.1 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
5.1.2 Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026)
5.2 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)
5.3 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region
6.1.1 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026)
6.1.2 APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2021-2026)
6.2 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)
6.3 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly by Country
7.1.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
7.1.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026)
7.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)
7.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly by Country
8.1.1 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
8.1.2 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026)
8.2 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)
8.3 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Respiratory Syncytial Virus Vaccine for the Elderly
10.3 Manufacturing Process Analysis of Respiratory Syncytial Virus Vaccine for the Elderly
10.4 Industry Chain Structure of Respiratory Syncytial Virus Vaccine for the Elderly
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
11.3 Respiratory Syncytial Virus Vaccine for the Elderly Customer
12 WORLD FORECAST REVIEW FOR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY BY GEOGRAPHIC REGION
12.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Region
12.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecast by Region (2027-2032)
12.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecast by Type (2027-2032)
12.7 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.2.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Moderna
13.3.1 Moderna Company Information
13.3.2 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Moderna Main Business Overview
13.3.5 Moderna Latest Developments
13.4 Daiichi Sankyo
13.4.1 Daiichi Sankyo Company Information
13.4.2 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.4.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Daiichi Sankyo Main Business Overview
13.4.5 Daiichi Sankyo Latest Developments
13.5 Icosavax
13.5.1 Icosavax Company Information
13.5.2 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.5.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Icosavax Main Business Overview
13.5.5 Icosavax Latest Developments
13.6 Sanofi
13.6.1 Sanofi Company Information
13.6.2 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Sanofi Main Business Overview
13.6.5 Sanofi Latest Developments
13.7 Blue Lake Biotechnology
13.7.1 Blue Lake Biotechnology Company Information
13.7.2 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.7.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Blue Lake Biotechnology Main Business Overview
13.7.5 Blue Lake Biotechnology Latest Developments
13.8 Advaccine
13.8.1 Advaccine Company Information
13.8.2 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.8.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Advaccine Main Business Overview
13.8.5 Advaccine Latest Developments
13.9 Starna Therapeutics
13.9.1 Starna Therapeutics Company Information
13.9.2 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.9.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Starna Therapeutics Main Business Overview
13.9.5 Starna Therapeutics Latest Developments
13.10 Immorna
13.10.1 Immorna Company Information
13.10.2 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.10.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Immorna Main Business Overview
13.10.5 Immorna Latest Developments
13.11 Clover Biopharma
13.11.1 Clover Biopharma Company Information
13.11.2 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Clover Biopharma Main Business Overview
13.11.5 Clover Biopharma Latest Developments
13.12 Innorna
13.12.1 Innorna Company Information
13.12.2 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Innorna Main Business Overview
13.12.5 Innorna Latest Developments
13.13 RNAimmune
13.13.1 RNAimmune Company Information
13.13.2 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.13.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 RNAimmune Main Business Overview
13.13.5 RNAimmune Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Respiratory Syncytial Virus Vaccine for the Elderly by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Respiratory Syncytial Virus Vaccine for the Elderly by Country/Region, 2021, 2025 & 2032
2.2 Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type
2.2.1 Recombinant Protein Vaccine
2.2.2 Nucleic Acid Vaccines
2.2.3 Others
2.2.4 Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type
2.2.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
2.2.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Type (2021-2026)
2.3 Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application
2.3.1 Hospital
2.3.2 Centers for Disease Control and Prevention
2.3.3 Others
2.3.4 Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application
2.3.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Market Share by Application (2021-2026)
2.3.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Breakdown Data by Company
3.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales by Company (2021-2026)
3.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Company (2021-2026)
3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue by Company (2021-2026)
3.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company (2021-2026)
3.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Company (2021-2026)
3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Company
3.4 Key Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Product Location Distribution
3.4.2 Players Respiratory Syncytial Virus Vaccine for the Elderly Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY BY GEOGRAPHIC REGION
4.1 World Historic Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Geographic Region (2021-2026)
4.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country/Region (2021-2026)
4.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales by Country/Region (2021-2026)
4.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue by Country/Region (2021-2026)
4.3 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth
4.4 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth
4.5 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth
4.6 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth
5 AMERICAS
5.1 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country
5.1.1 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
5.1.2 Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026)
5.2 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)
5.3 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region
6.1.1 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026)
6.1.2 APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2021-2026)
6.2 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)
6.3 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly by Country
7.1.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
7.1.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026)
7.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)
7.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly by Country
8.1.1 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)
8.1.2 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026)
8.2 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)
8.3 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Respiratory Syncytial Virus Vaccine for the Elderly
10.3 Manufacturing Process Analysis of Respiratory Syncytial Virus Vaccine for the Elderly
10.4 Industry Chain Structure of Respiratory Syncytial Virus Vaccine for the Elderly
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
11.3 Respiratory Syncytial Virus Vaccine for the Elderly Customer
12 WORLD FORECAST REVIEW FOR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY BY GEOGRAPHIC REGION
12.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Region
12.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecast by Region (2027-2032)
12.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecast by Type (2027-2032)
12.7 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 GSK
13.1.1 GSK Company Information
13.1.2 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 GSK Main Business Overview
13.1.5 GSK Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.2.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Moderna
13.3.1 Moderna Company Information
13.3.2 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Moderna Main Business Overview
13.3.5 Moderna Latest Developments
13.4 Daiichi Sankyo
13.4.1 Daiichi Sankyo Company Information
13.4.2 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.4.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Daiichi Sankyo Main Business Overview
13.4.5 Daiichi Sankyo Latest Developments
13.5 Icosavax
13.5.1 Icosavax Company Information
13.5.2 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.5.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Icosavax Main Business Overview
13.5.5 Icosavax Latest Developments
13.6 Sanofi
13.6.1 Sanofi Company Information
13.6.2 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Sanofi Main Business Overview
13.6.5 Sanofi Latest Developments
13.7 Blue Lake Biotechnology
13.7.1 Blue Lake Biotechnology Company Information
13.7.2 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.7.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Blue Lake Biotechnology Main Business Overview
13.7.5 Blue Lake Biotechnology Latest Developments
13.8 Advaccine
13.8.1 Advaccine Company Information
13.8.2 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.8.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Advaccine Main Business Overview
13.8.5 Advaccine Latest Developments
13.9 Starna Therapeutics
13.9.1 Starna Therapeutics Company Information
13.9.2 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.9.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Starna Therapeutics Main Business Overview
13.9.5 Starna Therapeutics Latest Developments
13.10 Immorna
13.10.1 Immorna Company Information
13.10.2 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.10.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Immorna Main Business Overview
13.10.5 Immorna Latest Developments
13.11 Clover Biopharma
13.11.1 Clover Biopharma Company Information
13.11.2 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Clover Biopharma Main Business Overview
13.11.5 Clover Biopharma Latest Developments
13.12 Innorna
13.12.1 Innorna Company Information
13.12.2 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Innorna Main Business Overview
13.12.5 Innorna Latest Developments
13.13 RNAimmune
13.13.1 RNAimmune Company Information
13.13.2 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
13.13.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 RNAimmune Main Business Overview
13.13.5 RNAimmune Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Recombinant Protein Vaccine
Table 4. Major Players of Nucleic Acid Vaccines
Table 5. Major Players of Others
Table 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
Table 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
Table 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2026) & ($ million)
Table 9. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2026)
Table 10. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale by Application (2021-2026) & (Dose)
Table 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Market Share by Application (2021-2026)
Table 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2026) & ($ million)
Table 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2026)
Table 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Application (2021-2026) & (US$/Dose)
Table 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Company (2021-2026) & (Dose)
Table 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Company (2021-2026)
Table 18. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Company (2021-2026)
Table 20. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Company (2021-2026) & (US$/Dose)
Table 21. Key Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Producing Area Distribution and Sales Area
Table 22. Players Respiratory Syncytial Virus Vaccine for the Elderly Products Offered
Table 23. Respiratory Syncytial Virus Vaccine for the Elderly Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Region (2021-2026) & (Dose)
Table 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Geographic Region (2021-2026)
Table 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country/Region (2021-2026) & (Dose)
Table 31. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country/Region (2021-2026)
Table 32. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Dose)
Table 35. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026)
Table 36. Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
Table 38. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)
Table 39. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026) & (Dose)
Table 40. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2021-2026)
Table 41. APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
Table 43. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)
Table 44. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Dose)
Table 45. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
Table 47. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)
Table 48. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Dose)
Table 49. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
Table 51. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)
Table 52. Key Market Drivers & Growth Opportunities of Respiratory Syncytial Virus Vaccine for the Elderly
Table 53. Key Market Challenges & Risks of Respiratory Syncytial Virus Vaccine for the Elderly
Table 54. Key Industry Trends of Respiratory Syncytial Virus Vaccine for the Elderly
Table 55. Respiratory Syncytial Virus Vaccine for the Elderly Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Respiratory Syncytial Virus Vaccine for the Elderly Distributors List
Table 58. Respiratory Syncytial Virus Vaccine for the Elderly Customer List
Table 59. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Region (2027-2032) & (Dose)
Table 60. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Dose)
Table 62. Americas Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Region (2027-2032) & (Dose)
Table 64. APAC Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Dose)
Table 66. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Dose)
Table 68. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Type (2027-2032) & (Dose)
Table 70. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Application (2027-2032) & (Dose)
Table 72. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. GSK Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 74. GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 75. GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 76. GSK Main Business
Table 77. GSK Latest Developments
Table 78. Pfizer Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 79. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 80. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 81. Pfizer Main Business
Table 82. Pfizer Latest Developments
Table 83. Moderna Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 84. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 85. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 86. Moderna Main Business
Table 87. Moderna Latest Developments
Table 88. Daiichi Sankyo Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 89. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 90. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. Daiichi Sankyo Main Business
Table 92. Daiichi Sankyo Latest Developments
Table 93. Icosavax Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 94. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 95. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. Icosavax Main Business
Table 97. Icosavax Latest Developments
Table 98. Sanofi Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 99. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 100. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Sanofi Main Business
Table 102. Sanofi Latest Developments
Table 103. Blue Lake Biotechnology Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 104. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 105. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Blue Lake Biotechnology Main Business
Table 107. Blue Lake Biotechnology Latest Developments
Table 108. Advaccine Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 109. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 110. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Advaccine Main Business
Table 112. Advaccine Latest Developments
Table 113. Starna Therapeutics Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 114. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 115. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. Starna Therapeutics Main Business
Table 117. Starna Therapeutics Latest Developments
Table 118. Immorna Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 119. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 120. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. Immorna Main Business
Table 122. Immorna Latest Developments
Table 123. Clover Biopharma Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 124. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 125. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Clover Biopharma Main Business
Table 127. Clover Biopharma Latest Developments
Table 128. Innorna Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 129. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 130. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. Innorna Main Business
Table 132. Innorna Latest Developments
Table 133. RNAimmune Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 134. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 135. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 136. RNAimmune Main Business
Table 137. RNAimmune Latest Developments
Table 1. Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Recombinant Protein Vaccine
Table 4. Major Players of Nucleic Acid Vaccines
Table 5. Major Players of Others
Table 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
Table 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
Table 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2026) & ($ million)
Table 9. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2026)
Table 10. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Type (2021-2026) & (US$/Dose)
Table 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale by Application (2021-2026) & (Dose)
Table 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Market Share by Application (2021-2026)
Table 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2026) & ($ million)
Table 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2026)
Table 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Application (2021-2026) & (US$/Dose)
Table 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Company (2021-2026) & (Dose)
Table 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Company (2021-2026)
Table 18. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Company (2021-2026)
Table 20. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Company (2021-2026) & (US$/Dose)
Table 21. Key Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Producing Area Distribution and Sales Area
Table 22. Players Respiratory Syncytial Virus Vaccine for the Elderly Products Offered
Table 23. Respiratory Syncytial Virus Vaccine for the Elderly Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Region (2021-2026) & (Dose)
Table 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Geographic Region (2021-2026)
Table 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country/Region (2021-2026) & (Dose)
Table 31. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country/Region (2021-2026)
Table 32. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Dose)
Table 35. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026)
Table 36. Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
Table 38. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)
Table 39. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026) & (Dose)
Table 40. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2021-2026)
Table 41. APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
Table 43. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)
Table 44. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Dose)
Table 45. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
Table 47. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)
Table 48. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Dose)
Table 49. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
Table 51. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)
Table 52. Key Market Drivers & Growth Opportunities of Respiratory Syncytial Virus Vaccine for the Elderly
Table 53. Key Market Challenges & Risks of Respiratory Syncytial Virus Vaccine for the Elderly
Table 54. Key Industry Trends of Respiratory Syncytial Virus Vaccine for the Elderly
Table 55. Respiratory Syncytial Virus Vaccine for the Elderly Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Respiratory Syncytial Virus Vaccine for the Elderly Distributors List
Table 58. Respiratory Syncytial Virus Vaccine for the Elderly Customer List
Table 59. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Region (2027-2032) & (Dose)
Table 60. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Dose)
Table 62. Americas Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Region (2027-2032) & (Dose)
Table 64. APAC Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Dose)
Table 66. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Dose)
Table 68. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Type (2027-2032) & (Dose)
Table 70. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Application (2027-2032) & (Dose)
Table 72. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. GSK Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 74. GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 75. GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 76. GSK Main Business
Table 77. GSK Latest Developments
Table 78. Pfizer Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 79. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 80. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 81. Pfizer Main Business
Table 82. Pfizer Latest Developments
Table 83. Moderna Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 84. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 85. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 86. Moderna Main Business
Table 87. Moderna Latest Developments
Table 88. Daiichi Sankyo Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 89. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 90. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. Daiichi Sankyo Main Business
Table 92. Daiichi Sankyo Latest Developments
Table 93. Icosavax Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 94. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 95. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. Icosavax Main Business
Table 97. Icosavax Latest Developments
Table 98. Sanofi Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 99. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 100. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Sanofi Main Business
Table 102. Sanofi Latest Developments
Table 103. Blue Lake Biotechnology Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 104. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 105. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Blue Lake Biotechnology Main Business
Table 107. Blue Lake Biotechnology Latest Developments
Table 108. Advaccine Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 109. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 110. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Advaccine Main Business
Table 112. Advaccine Latest Developments
Table 113. Starna Therapeutics Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 114. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 115. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. Starna Therapeutics Main Business
Table 117. Starna Therapeutics Latest Developments
Table 118. Immorna Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 119. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 120. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. Immorna Main Business
Table 122. Immorna Latest Developments
Table 123. Clover Biopharma Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 124. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 125. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Clover Biopharma Main Business
Table 127. Clover Biopharma Latest Developments
Table 128. Innorna Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 129. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 130. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. Innorna Main Business
Table 132. Innorna Latest Developments
Table 133. RNAimmune Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors
Table 134. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
Table 135. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 136. RNAimmune Main Business
Table 137. RNAimmune Latest Developments
LIST OF FIGURES
Figure 1. Picture of Respiratory Syncytial Virus Vaccine for the Elderly
Figure 2. Respiratory Syncytial Virus Vaccine for the Elderly Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate 2021-2032 (Dose)
Figure 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country/Region (2025)
Figure 10. Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Recombinant Protein Vaccine
Figure 12. Product Picture of Nucleic Acid Vaccines
Figure 13. Product Picture of Others
Figure 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type in 2026
Figure 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2026)
Figure 16. Respiratory Syncytial Virus Vaccine for the Elderly Consumed in Hospital
Figure 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Market: Hospital (2021-2026) & (Dose)
Figure 18. Respiratory Syncytial Virus Vaccine for the Elderly Consumed in Centers for Disease Control and Prevention
Figure 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Market: Centers for Disease Control and Prevention (2021-2026) & (Dose)
Figure 20. Respiratory Syncytial Virus Vaccine for the Elderly Consumed in Others
Figure 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Market: Others (2021-2026) & (Dose)
Figure 22. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Market Share by Application (2025)
Figure 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application in 2026
Figure 24. Respiratory Syncytial Virus Vaccine for the Elderly Sales by Company in 2026 (Dose)
Figure 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Company in 2026
Figure 26. Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company in 2026 ($ millions)
Figure 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Company in 2026
Figure 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)
Figure 31. Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 ($ millions)
Figure 32. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)
Figure 33. APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 ($ millions)
Figure 34. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)
Figure 35. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)
Figure 37. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 ($ millions)
Figure 38. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country in 2026
Figure 39. Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2026)
Figure 40. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
Figure 41. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)
Figure 42. United States Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region in 2026
Figure 47. APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2021-2026)
Figure 48. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
Figure 49. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)
Figure 50. China Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 54. India Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country in 2026
Figure 58. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2026)
Figure 59. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
Figure 60. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)
Figure 61. Germany Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 62. France Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)
Figure 69. Egypt Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Respiratory Syncytial Virus Vaccine for the Elderly in 2026
Figure 75. Manufacturing Process Analysis of Respiratory Syncytial Virus Vaccine for the Elderly
Figure 76. Industry Chain Structure of Respiratory Syncytial Virus Vaccine for the Elderly
Figure 77. Channels of Distribution
Figure 78. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Forecast by Region (2027-2032)
Figure 79. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Respiratory Syncytial Virus Vaccine for the Elderly
Figure 2. Respiratory Syncytial Virus Vaccine for the Elderly Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate 2021-2032 (Dose)
Figure 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country/Region (2025)
Figure 10. Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Recombinant Protein Vaccine
Figure 12. Product Picture of Nucleic Acid Vaccines
Figure 13. Product Picture of Others
Figure 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type in 2026
Figure 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2026)
Figure 16. Respiratory Syncytial Virus Vaccine for the Elderly Consumed in Hospital
Figure 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Market: Hospital (2021-2026) & (Dose)
Figure 18. Respiratory Syncytial Virus Vaccine for the Elderly Consumed in Centers for Disease Control and Prevention
Figure 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Market: Centers for Disease Control and Prevention (2021-2026) & (Dose)
Figure 20. Respiratory Syncytial Virus Vaccine for the Elderly Consumed in Others
Figure 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Market: Others (2021-2026) & (Dose)
Figure 22. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Market Share by Application (2025)
Figure 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application in 2026
Figure 24. Respiratory Syncytial Virus Vaccine for the Elderly Sales by Company in 2026 (Dose)
Figure 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Company in 2026
Figure 26. Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company in 2026 ($ millions)
Figure 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Company in 2026
Figure 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Geographic Region (2021-2026)
Figure 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Geographic Region in 2026
Figure 30. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)
Figure 31. Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 ($ millions)
Figure 32. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)
Figure 33. APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 ($ millions)
Figure 34. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)
Figure 35. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 ($ millions)
Figure 36. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)
Figure 37. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 ($ millions)
Figure 38. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country in 2026
Figure 39. Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2026)
Figure 40. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
Figure 41. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)
Figure 42. United States Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 43. Canada Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 44. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 45. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 46. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region in 2026
Figure 47. APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2021-2026)
Figure 48. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
Figure 49. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)
Figure 50. China Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 51. Japan Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 52. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 53. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 54. India Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 55. Australia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 56. China Taiwan Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 57. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country in 2026
Figure 58. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2026)
Figure 59. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
Figure 60. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)
Figure 61. Germany Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 62. France Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 63. UK Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 64. Italy Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 65. Russia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 66. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026)
Figure 67. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)
Figure 68. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)
Figure 69. Egypt Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 70. South Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 71. Israel Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 72. Turkey Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 73. GCC Countries Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Respiratory Syncytial Virus Vaccine for the Elderly in 2026
Figure 75. Manufacturing Process Analysis of Respiratory Syncytial Virus Vaccine for the Elderly
Figure 76. Industry Chain Structure of Respiratory Syncytial Virus Vaccine for the Elderly
Figure 77. Channels of Distribution
Figure 78. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Forecast by Region (2027-2032)
Figure 79. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share Forecast by Region (2027-2032)
Figure 80. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Forecast by Type (2027-2032)
Figure 81. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share Forecast by Type (2027-2032)
Figure 82. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Forecast by Application (2027-2032)
Figure 83. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share Forecast by Application (2027-2032)
